Prix CANbridge Pharmaceuticals Inc. (01228.HK)

CANbridge Pharmaceuticals Inc. operates as a rare disease-focused biopharmaceutical company committed to the research, development and commercialization of transformative therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 45 full-time employees. The company went IPO on 2021-12-10. The company is focused on research, development and commercialization of transformative therapies for rare disease. The company has a drug portfolio, with three approved drugs and a pipeline of eight assets, targeting rare disease indications that have unmet needs. These include Hunter syndrome and other lysosomal storage disorders, paroxysmal nocturnal hemoglobinuria and other complement-mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases and neuromuscular diseases. Its pipeline includes Hunterase, Livmarli, CAN106, and CAN103. Hunterase is an enzyme replacement therapy for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome. Livmarli an oral, minimally absorbed, reversible inhibitor of the ileal bile acid transporter that is under development to treat rare cholestatic liver diseases including Alagille syndrome and progressive familial intrahepatic cholestasis.